EN
P-004527/2018
Answer given by Mr Andriukaitis
on behalf of the European Commission
(31.10.2018)

The Commission notes that the European Medicines Agency's (EMA), like other EU actors, has prepared business continuity plans to address certain consequences stemming from the United Kingdom leaving the Union. For more information on these plans, including on the Agency's participation in stakeholder meetings, the Commission invites the Honourable Member to directly address the Agency.

The Commission notes from the Agency's plans that core regulatory tasks on marketing authorisation related opinions and surveillance of individual medicinal products are currently not being targeted and that the timeframes laid down in the legislation are therefore currently not being questioned. As regards international collaboration, and in particular harmonisation activities, the Commission and the Agency are working closely on the prioritisation in order to maintain the EU's leading role at global level, despite the temporary scaling down of some identified tasks of the Agency.

The Commission supports the Agency's focus on key stakeholders meetings and rational use of resources for the smooth running of its core tasks.